Rapid Therapeutic Science Laboratories, Inc. (RTSL) Comparison with companies in other sectors?

Rapid Therapeutic Science Laboratories, Inc. has a share price of 8.83M. You can analyze Rapid Therapeutic Science Laboratories, Inc. (RTSL) competitors across different market sectors through stock heatmaps.

What are RTSL's NET and operating margins?

Rapid Therapeutic Science Laboratories, Inc. (RTSL) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does RTSL's earnings per share (EPS) trend reflect its financial momentum?

Rapid Therapeutic Science Laboratories, Inc. (RTSL) EPS is 0.01 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Rapid Therapeutic Science Laboratories, Inc. is 0.70, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Rapid Therapeutic Science Laboratories, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Rapid Therapeutic Science Laboratories, Inc. like P/E which is -0.03, P/B which is -0.02, and PEG which is -0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Rapid Therapeutic Science Laboratories, Inc.

RTSL•PNK

Healthcare

Medical - Devices

$0.007

$0.00(0.00%)

Fundamental Analysis of Rapid Therapeutic Science Laboratories, Inc. (RTSL)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.01

P/E Ratio

0.70

ROE

0.75%

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$61.83K

Shares OutstandingTotal number of shares issued

$8.83M

Book Value/ShareNet worth per share

$-0.41

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.01

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

74.89%

ROAReturn on total assets

-75.13%

ROCEReturn on capital employed

46.60%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.15

Cash/ShareCash and equivalents per share

$-0.05

FCF YieldFree cash flow as percentage of market cap

-1926.15%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for RTSLFinancial Ratios Analysis details for RTSL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for RTSLSector Benchmarking details for RTSL are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Rapid Therapeutic Science Laboratories, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Rapid Therapeutic Science Laboratories, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Rapid Therapeutic Science Laboratories, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Rapid Therapeutic Science Laboratories, Inc.

For Rapid Therapeutic Science Laboratories, Inc., essential financial indicators include EPS 0.01, PE 0.70, and ROE 0.75. These key ratios reveal insights into Rapid Therapeutic Science Laboratories, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Rapid Therapeutic Science Laboratories, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Rapid Therapeutic Science Laboratories, Inc.

Metrics like Net Margin - and ROA -75.13% shed light on how well Rapid Therapeutic Science Laboratories, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Rapid Therapeutic Science Laboratories, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Rapid Therapeutic Science Laboratories, Inc.

Using ratios such as P/B Ratio -0.02 and PEG Ratio -0.00, investors can assess whether Rapid Therapeutic Science Laboratories, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Rapid Therapeutic Science Laboratories, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Rapid Therapeutic Science Laboratories, Inc.

Financial health indicators, such as Debt/Equity Ratio -1.22 and Cash Flow $-0.15, provide a snapshot of Rapid Therapeutic Science Laboratories, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Rapid Therapeutic Science Laboratories, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Rapid Therapeutic Science Laboratories, Inc.

Investing in Rapid Therapeutic Science Laboratories, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Rapid Therapeutic Science Laboratories, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;